BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, Nevens F, Suh KS, Fischer L, Jin Joo D, Fung J, Joh JW, Kaido T, Grant D, Meier M, Rauer B, Sips C, Kaneko S, Levy G. Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials. Transplantation 2021;105:1564-75. [PMID: 33741847 DOI: 10.1097/TP.0000000000003394] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Umemura K, Mita A, Ohno Y, Masuda Y, Yoshizawa K, Kubota K, Notake T, Hosoda K, Kamachi A, Goto T, Tomida H, Yamazaki S, Shimizu A, Soejima Y. Late-onset Chronic Kidney Disease Over 2 Decades After Pediatric Liver Transplantation: A Single-center, Retrospective Study. Transplantation 2023. [PMID: 36624564 DOI: 10.1097/TP.0000000000004465] [Reference Citation Analysis]
2 Chen J, Shen T, Li J, Ling S, Yang Z, Wang G, Sun L, Yang Z, Zhuang L, Gao J, Guo W, Li J, Xu S, Wei Q, Zheng S, Xu X. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition). Chin Med J (Engl) 2023. [PMID: 36602405 DOI: 10.1097/CM9.0000000000002515] [Reference Citation Analysis]
3 Cui J, Spann A, Shingina A, Schaefer H, Slaughter JC, Matsuoka L, Alexopoulos S, Izzy M. Predictors of renal recovery in recipients of liver transplant alone who met 2017 simultaneous liver-kidney transplant criteria. Clin Transplant 2022;36:e14812. [PMID: 36065935 DOI: 10.1111/ctr.14812] [Reference Citation Analysis]
4 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Hyung Soon Lee, Joon Ye Kim, Simon Weonsang Ro, Myoung Soo Kim, Haeryoung Kim, Dong Jin Joo. Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer. Yonsei Med J 2022;63. [PMID: 36303309 DOI: 10.3349/ymj.2022.0247] [Reference Citation Analysis]
6 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Grootjans H, Verschuuren EAM, van Gemert JP, Kerstjens HAM, Bakker SJL, Berger SP, Gan CT. Chronic kidney disease after lung transplantation in a changing era. Transplant Rev (Orlando) 2022;36:100727. [PMID: 36152358 DOI: 10.1016/j.trre.2022.100727] [Reference Citation Analysis]
8 Bhangui P. Liver transplantation and portal vein tumour thrombus: futile enterprise? Curr Opin Organ Transplant 2022;27:312-9. [PMID: 36354257 DOI: 10.1097/MOT.0000000000000997] [Reference Citation Analysis]
9 Cholongitas E. What Is the Impact of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation 2022;106:e189. [PMID: 35192584 DOI: 10.1097/TP.0000000000003980] [Reference Citation Analysis]
10 Cho SH, Crone C. Neuropsychiatric Adverse Effects of Immunosuppressant Agents. Transplant Psychiatry 2022. [DOI: 10.1007/978-3-031-15052-4_35] [Reference Citation Analysis]
11 Panackel C, Mathew JF, Fawas N M, Jacob M. Immunosuppressive Drugs in Liver Transplant: An Insight. J Clin Exp Hepatol 2022;12:1557-71. [PMID: 36340316 DOI: 10.1016/j.jceh.2022.06.007] [Reference Citation Analysis]
12 Syutkin VE, Salienko AA, Zhuravel SV, Novruzbekov MS. Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion. RJTAO 2021;23:32-41. [DOI: 10.15825/25/1995-1191-2021-4-32-41] [Reference Citation Analysis]
13 Hsu PJ, Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Wu TJ, Chou HS, Chan KM, Lee WC, Lee CF. Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients. Curr Oncol 2021;28:4281-90. [PMID: 34898547 DOI: 10.3390/curroncol28060364] [Reference Citation Analysis]
14 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Kim JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation? Clin Mol Hepatol 2021;27:562-3. [PMID: 34551504 DOI: 10.3350/cmh.2021.0276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Sung PS, Han JW, Seo C, Ahn J, Lee SK, Nam HC, Choi HJ, You YK, Jang JW, Choi JY, Yoon SK. Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant. Front Pharmacol 2021;12:685176. [PMID: 34326770 DOI: 10.3389/fphar.2021.685176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]